|
|
INYVAX - Optimisation of the development of poverty related diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges
| Third-party funded project |
| Project title |
INYVAX - Optimisation of the development of poverty related diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges |
| Principal Investigator(s) |
Heininger, Ulrich
|
| Co-Investigator(s) |
Heininger, Ulrich
|
| Organisation / Research unit |
Bereich Kinder- und Jugendheilkunde (Klinik) / Pädiatrie (Frey) |
| Project start |
01.02.2009 |
| Probable end |
31.01.2011 |
| Status |
Completed |
| Abstract |
A number of new vaccines are being developed against poverty-related infectious diseases of major public health importance at a global level. The development of these vaccines is facing the same kind of challenges and gaps, which still prevent:
the establishment of readily accessible formulation and scale-up process development capacity for neglected disease vaccines.
the establishment of a systematic approach for prioritising formulation of vaccine candidates using accepted pre-clinical criteria.
the development of information-sharing tools to strengthen connections between the scientists, the developers and the clinical investigators.
To address those challenges, the European vaccine community needs to establish a shared vision and goals and to identify the activities that could address some of the above-mentioned challenges.
A cooperation between the different groups of PRD vaccine developers will bring innovative approaches for accelerating the development of effective vaccines. Among those challenges, several can be addressed through coordination across poverty related diseases, such as:
Difficulties in accessing some technology platforms, such as synthetic peptides/recombinant proteins and expertise for GMP development, therefore allowing rational decisions to be made on the best industrial approach for pharmaceutical development.
Difficulties in accessing certain know-how, such as lyophilisation and lack of formulation platforms accessible to academic groups.
Difficulties in accessing some delivery platforms, such as adjuvants and virus-like particles for GMP development and/or to assess the quality and regulatory compliance of those platforms.
Difficulties in harmonising the safety data collection.
The insufficient number of trained scientists able to undertake leadership roles in vaccine development. |
| Financed by |
Commission of the European Union
|
| |
|
|
MCSS v5.8 PRO. 0.427 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
23/04/2024
Research Database / FORSCHUNGSDATENBANK
|
